Rahul Atul Parikh, Benjamin Herzberg, Mark N. Stein, Shumei Kato, Minal A. Barve, David R. Spigel, Benjamin Garmezy, Alexander Philipovskiy, Gopa Iyer, Alissa Jamie Cooper, Manav Korpal, Maciej Cabanski, Carolina Perdomo Ortiz, Ralph Tiedt, Lisa D. Cleary, Tess Schmalbach, Markus Warmuth, Filip Janku, Alexander I. Spira. "A phase 1/2 study of MRT-2359, a highly selective oral GSPT1 molecular glue degrader (MGD), in combination with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) harboring AR ligand binding domain (LBD) mutations.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.7_suppl.161